Chemical formula: C₈₈H₉₇Cl₂N₉O₃₃ Molecular mass: 1,879.7 g/mol
Teicoplanin inhibits the growth of susceptible organisms by interfering with cell-wall biosynthesis at a site different from that affected by beta-lactams. Peptidoglycan synthesis is blocked by specific binding to D-alanyl-D-alanine residues.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| J01XA02 | Teicoplanin | J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01X Other antibacterials → J01XA Glycopeptide antibacterials |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| TARGOCID Powder for solution for injection, infusion or oral solution | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Teicoplanin is an active ingredient of these brands:
Austria (AT)Croatia (HR)Cyprus (CY)Estonia (EE)Finland (FI)France (FR)Ireland (IE)Italy (IT)Japan (JP)Mexico (MX)Netherlands (NL)New Zealand (NZ)Romania (RO)Singapore (SG)Spain (ES)Tunisia (TN)Turkey (TR)United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
